WebJun 13, 2011 · RLY5016-205 was an open-label, randomized, dose ranging study to determine the optimal starting dose, efficacy and safety of patiromer in treating hyperkalemia in hypertensive patients with nephropathy due to type 2 diabetes mellitus (T2DM) who were already receiving Angiotensin-converting Enzyme Inhibitor (ACEI) … WebApr 2, 2024 · The majority of patients with heart failure with reduced ejection fraction (HFrEF) and renin-angiotensin-aldosterone system inhibitor (RAASi)-related …
Patiromer Improves Potassium Levels in CKD patients with HFrEF: …
WebThere has been considerable clinical evidence for the use of potassium binders in the management of hyperkalemia in patients with heart failure. The most recent study is the DIAMOND trial, and results were just presented at the American College of Cardiology 2024 meeting. So what does it mean to “enable” RAASi therapy, and how does this impact … WebMar 16, 2024 · Prof. Van der Meer sums up the evidence of trials with the two novel potassium binders patiromer and ZS-9. Also, he presents the details of the design of the DIAMOND trial. ... he presents the details of the design of the DIAMOND trial. ... Managing Patients with CKD, Hyperkalemia, and Continued RAASi Therapy Through a Case … shaped like a rhomboid
Patiromer for the management of hyperkalaemia in patients …
WebThe DIAMOND trial recently released topline results, adding to the growing clinical evidence for the use of potassium binders in the management of hyperkalemia in patients with heart failure. So what do the data mean for our patients? Join Dr. Stefan Anker and Dr. Javed Butler as they discuss the value of these results and make sure you’re staying up to date … WebApr 5, 2024 · The patients on patiromer showed a 0.03 mEq/L mean rise in serum potassium levels from randomization to the end of the study, the primary endpoint, compared with a 0.13 mEq/L mean increase for ... WebSep 24, 2024 · DIAMOND trial was designed to evaluate patiromer for the management of hyperkalemia in patients receiving RAAS inhibitors for heart failure with reduced ejection fraction (HFrEF) [2]. 1195 patients with RAAS inhibitor related current or previous hyperkalemia were enrolled in the 12 week run-in phase with patiromer and optimization … shaped like a top